Dasiglucagon, marketed under the brand names Zegalogue Autoinjector and Zegalogue Prefilled Syringe, is an injectable medication used to treat severe hypoglycemia (very low blood sugar) in adults and children aged six years and older with diabetes.Dasiglucagon (Zegalogue) was approved by the U.S. Food and Drug Administration (FDA) on March 22, 2021. This approval introduced a new emergency treatment option for managing severe hypoglycemia, providing a fast-acting solution for diabetic patients in critical situations.
Dasiglucagon works by stimulating the liver to release stored glucose into the bloodstream, thereby rapidly increasing blood sugar levels. It is administered subcutaneously (under the skin) and is designed for use in emergency situations where immediate action is required to prevent severe complications from hypoglycemia, such as seizures, coma, or death.
Dosage Form: Dasiglucagon is available as a subcutaneous solution with a concentration of 0.6 mg/0.6 mL.
Dosage Instructions:
Administration:
Common Side Effects:
Serious Side Effects:
Warnings:
Storage:
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!